Towards better management of glaucoma in India

Rewri, Parveen

doi:10.4103/ijo.ijo_379_23

Cited by 7 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By 2040, 27.8 million more people in Asia are expected to suffer from glaucoma; China and India will bear the greatest part of this burden. Glaucoma is one of the main causes of permanent blindness in India, accounting for 5.5% of all cases of blindness and 1.2 million cases of blindness" [5].…”

Section: Introductionmentioning

confidence: 99%

Glaucoma (Eye Disease) and its Associated Diagnosis and Treatment Process: A Schematic Concise Review

Srivastav,

Taj,

Singh

et al. 2024

View full text Add to dashboard Cite

A class of eye conditions known as glaucoma can result in blindness and visual loss by harming the optic nerve, a nerve located at the back of the eye. You might not notice the symptoms at first because they can appear so slowly. A thorough dilated eye exam is the only way to determine if you have glaucoma. While there is no known cure for glaucoma, vision protection and damage can frequently be stopped with early intervention. Primary open-angle and angle-closure glaucoma, as well as secondary open and angle-closure glaucoma, are the four main types of adult glaucoma. Prescription eye drops are the most popular form of treatment for glaucoma. They function by reducing intraocular pressure and shielding your optic nerve from harm. Although these eye drops cannot reverse vision loss or treat glaucoma, they can prevent glaucoma from worsening. Prostaglandins are one type of prescription eye drop medication. By increasing the fluid's outflow from your eye, they aid in lowering intraocular pressure. Latanoprost (Xalatan), Travoprost (Travatan Z), Tafluprost (Zioptan), Bimatoprost (Lumigan), and Latanoprostene bunod (Vyzulta) are among the medications in this category. Alpha-adrenergic agonists, such as brimonidine (Altagan P) or Qoliana (Iopidine, apraclonidine) Beta-blockers such as Betimol, Istalol, Timoptic (timolol), and Betoptic (betaxolol) Inhibitors of carbonic anhydrases, such as Azopt (brinzolamide) and Trusopt (dorzolamide). In this review study, we discuss the aetiology, epidemiology, current management, and pathophysiology of glaucoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Glaucoma (Eye Disease) and its Associated Diagnosis and Treatment Process: A Schematic Concise Review

Srivastav,

Taj,

Singh

et al. 2024

View full text Add to dashboard Cite

show abstract

“…A progressive degenerative optic neuropathy, also known as glaucoma, results in typical vision field loss and abnormalities of the eyes' mechanics and function (such as loss of retinal ganglion cells and the ensuing damage to the optic nerve [1] . Glaucoma affects more than 64 million individuals aged 40 to 80 and was the main cause of irreversible blindness in the world.…”

Section: Introductionmentioning

confidence: 99%

“…India and China will account for the majority of the burden [2] . Glaucoma was one of the main causes of permanent blindness in India, causing blindness in 1.2 million individuals and 5.5% of all cases of blindness [3] . Hence, there was a growing need to address the difficulty of managing glaucoma as a public health issue at several levels, with a focus on the general public, service providers, and the eye healthcare system.…”

Section: Introductionmentioning

confidence: 99%

Expert opinion on netarsudil for the management of glaucoma in Indian settings

2024

Int. J. Med. Ophthalmol.

View full text Add to dashboard Cite

Background: Despite topical treatments for glaucoma are generally successful and well tolerated, there is a need for newer drugs to manage patients who are unable to tolerate previous topical treatments due to adverse effects or those who experience side effects or insufficient reduction in IOP with current medical treatments. Objective: The study was intended to gather diverse perspectives of experts on the use of netarsudil for the management of glaucoma. Methodology: This cross-sectional study examined the opinions of specialists from different parts of India about the usage of netarsudil for patients with glaucoma. Twenty-one questions in the survey aimed to elicit thoughts from specialists on whether they would advise netarsudil for glaucoma management. Results:The survey assessed the preferences of experts on prescribing netarsudil for glaucoma management. Out of 42 respondents, 57.14% indicated that glaucoma frequently affects individuals beyond the age of 50. The most commonly used method of diagnosing glaucoma was using a slit lamp examination and tonometer. The results demonstrate that 33.33% of respondents used travoprost and bimatoprost equally among prostaglandin analogues. Netarsudil was usually recommended for patients who were unable to control their symptoms with combination therapy, according to 47.61% of study participants. It was also suggested for individuals whose illnesses cannot be treated with prostaglandin analogues, according to about 14.28% of survey participants. Adding netarsudil can lower intraocular pressure (IOP) and delay the need for glaucoma laser or incisional surgery. According to a significant portion of respondents (30.95%), netarsudil can be prescribed for all patient with uncontrolled prostaglandin analogues, uncontrolled combination therapy, add-on therapy, or who needs surgery. Conclusion:The findings contribute to the knowledge base surrounding the use of netarsudil in clinical practice, providing insights into its potential role as a valuable therapeutic option for glaucoma patients.

show abstract